Avita Medical stock gained 5.91 percent near its yearly high
Avita Medical (RCEL) stock surged 5.91% to $12.72, nearing its 52-week high of $12.76, driven by an upward revision in its 2026 revenue guidance to $86 million-$89 million. The company also reported strong Q2 revenue of $21.7 million, beating consensus estimates, and expects to reach cash flow breakeven in Q4 2026, despite its current valuation exceeding analyst price targets.
Biotech Stocks At 52-Week Highs - CDNA, RCEL, AZTA, HNGE
Several biotech stocks, including CareDx Inc. (CDNA), AVITA Medical Inc. (RCEL), Azenta Inc. (AZTA), and Hinge Health Inc. (HNGE), reached 52-week highs on October 2, 2026. This surge was primarily driven by positive key catalysts such as encouraging quarterly reports and significant revenue growth. The article highlights each company's recent performance, product offerings, and financial outlook that contributed to their stock's strong performance.
AVITA Medical Inc Shs Chess Depository Interests repr 0.2 shs Revenue Breakdown – HAN:51KB
AVITA Medical Inc (HAN:51KB) reported total revenue of €57.03 million last year. The Commercial segment was the top-performing segment, generating €62.94 million, while the United States was the largest geographical contributor, accounting for €60.60 million.
Basic earnings per share (basic EPS) of AVITA Medical Inc Shs Chess Depository Interests repr 0.2 shs – HAN:51KB
This article focuses on the basic earnings per share (basic EPS) for AVITA Medical Inc. Shs Chess Depository Interests, traded under the ticker HAN:51KB on the Hannover Stock Exchange. It indicates that the market was closed with no trades recorded at the time of publication. The content also briefly touches upon financial data and market information available through TradingView.
Liquidity Mapping Around (RCEL) Price Events
This article provides a liquidity mapping analysis for Avita Medical Inc. (NASDAQ: RCEL), highlighting strong sentiment across all horizons and compelling upside potential due to the absence of resistance levels above the current price. It presents three AI-generated trading strategies—Position, Momentum Breakout, and Risk Hedging—tailored for different risk profiles, along with multi-timeframe signal analysis for support and resistance levels. The analysis suggests an overweight bias for RCEL.
Avita Medical Inc. (NASDAQ:RCEL) Receives Consensus Recommendation of "Moderate Buy" from Brokerages
Avita Medical Inc. (NASDAQ:RCEL) has received a "Moderate Buy" consensus rating from seven brokerages, with an average 12-month price target of $11.40. This rating is supported by five buy ratings, one hold, and one sell. The company recently reported strong quarterly revenues of $21.7 million, surpassing analyst estimates, and a narrower-than-expected adjusted loss per share, leading to several analysts raising their price targets.
Precision Trading with Avita Medical Inc. (RCEL) Risk Zones
This article provides an analysis of Avita Medical Inc. (RCEL) for precision trading, highlighting strong sentiment, a breakout, and no resistance levels above the current price. It outlines three AI-generated trading strategies—Position, Momentum Breakout, and Risk Hedging—along with multi-timeframe signal analysis indicating strong signals across all horizons. The piece emphasizes institutional-grade analysis and real-time trading signals for subscribers.
564,952 Shares in Avita Medical Inc. $RCEL Bought by BlackRock Inc.
BlackRock Inc. recently acquired 564,952 shares of Avita Medical Inc. (NASDAQ:RCEL), valued at approximately $2.33 million, giving it a 1.84% stake in the company. Institutional investors now collectively own 27.66% of Avita Medical, which recently surpassed quarterly revenue and EPS expectations. Analysts maintain a "Moderate Buy" consensus rating with an average price target of $11.40.
A live webcast will carry AVITA Medical’s Sept. 16 conference discussion.
AVITA Medical (RCEL) announced its participation in two investor conferences in September 2026: the Lake Street Best Ideas Growth Conference on September 10 and the Morgan Stanley Global Healthcare Conference on September 16. President and CEO Cary Vance and CFO David O’Toole will meet investors at both events and participate in a webcast fireside chat at the Morgan Stanley conference. A live audio webcast and 90-day replay of the fireside chat will be available on AVITA Medical’s Investor Relations website.
AVITA Medical to Participate in Lake Street Best Ideas Growth Conference and Morgan Stanley Healthcare Conference
AVITA Medical will participate in two investor conferences in September 2026: the Lake Street Best Ideas Growth Conference and the Morgan Stanley 24th Annual Global Healthcare Conference. Senior management, including CEO Cary Vance and CFO David O'Toole, will host investor meetings and a fireside chat to discuss the company's transformative acute wound care solutions. A webcast of the Morgan Stanley fireside chat will be available for replay on AVITA Medical's website.
Avita Medical Is Maintained at Buy by Lake Street
Lake Street has maintained a Buy rating on Avita Medical (RCEL). This indicates the firm's continued positive outlook on the company's stock.
AVITA Medical (RCEL) CFO boosts direct stake to 152,927 shares
AVITA Medical (RCEL) CFO David D. O'Toole amended a previous insider transaction, reporting the purchase of 2,000 shares of common stock at $3.97 per share on June 12, 2026. This amendment corrected the transaction code from "A" to "P". Following this purchase, O'Toole's directly held position, including unvested RSUs, totals 152,927 shares.
Avita Medical Inc. (RCEL) is a Great Momentum Stock: Should You Buy?
Avita Medical Inc. (RCEL) is identified as a strong momentum stock with a Zacks Rank of #2 (Buy) and a Momentum Style Score of B. The article highlights RCEL's significant short-term price increases, outperforming its industry and the S&P 500, along with positive earnings estimate revisions. These factors suggest it could be a promising pick for investors looking for near-term growth.
Avita Medical PermeaDerm Study Shows 70% Cost Reduction vs. Allograft
A new study on Avita Medical's PermeaDerm product demonstrated a 70% reduction in treatment costs compared to cadaveric allografts for temporary wound coverage. The PermeaDerm-I study, a randomized controlled trial involving 40 patients across 11 burn centers, also showed comparable healing and safety results, alongside significant reductions in preparation time due to simpler logistics. Surgeons highlighted PermeaDerm's ease of use, transparency, and predictable supply chain as advantages over allograft, with favorable outcomes even in large TBSA burns.
TD Cowen raises Avita Medical stock price target on PermeaDerm data
TD Cowen has increased its price target for Avita Medical (NASDAQ:RCEL) to $14.00 from $12.00, maintaining a Buy rating, citing enhanced confidence in PermeaDerm's commercial potential after positive clinical trial data and surgeon endorsements. The stock has surged 185% year-to-date, trading near its 52-week high, while recent financial reports also showed Avita Medical exceeding revenue estimates in Q2.
Avita Medical PermeaDerm Study Shows 70% Cost Reduction vs. Allograft
A new study by Avita Medical demonstrated that its PermeaDerm product reduced treatment costs by 70% compared to cadaveric allograft for temporary wound coverage, costing $148.70 versus $497.10 per 1% of total body surface area treated. The biosynthetic wound matrix also significantly cut preparation time while showing comparable graft take, application time, and eight-week wound healing outcomes. Surgeons noted PermeaDerm's standardized design, easier logistics, and potential use in larger burns, highlighting its transparency and consistent supply.
AVITA Medical Announces Positive PermeaDerm Study Results Demonstrating 70% Economic Advantage Over Allograft and Comparable Clinical Outcomes
AVITA Medical has announced positive results from its PermeaDerm study, showing a significant 70% economic advantage over allograft for full-thickness wounds. The study also demonstrated comparable clinical outcomes to allograft, positioning PermeaDerm as a cost-effective and clinically sound solution for wound care. These findings highlight the potential for PermeaDerm to improve patient care while reducing healthcare costs.
BTIG raises Avita Medical stock price target on positive trial data
BTIG has increased its price target for Avita Medical (NASDAQ:RCEL) to $11.00 from $7.00, maintaining a Buy rating, following positive results from the company's PermeaDerm-I study. This study demonstrated a significant economic advantage over allograft and comparable clinical outcomes, with PermeaDerm and Cohealyx expected to diversify Avita Medical’s revenue and growth. The stock has seen a substantial surge year-to-date, and analysts have revised earnings estimates upward, reflecting strong financial performance and strategic moves by the company.
Avita Medical Inc. (NASDAQ:RCEL) Receives Average Rating of "Moderate Buy" from Analysts
Avita Medical Inc. (NASDAQ:RCEL) has received a "Moderate Buy" consensus rating from analysts, with five out of seven recommending a buy. The average 12-month price target is $8.25. The company recently reported better-than-expected quarterly earnings and revenue, and insiders have purchased 35,200 shares in the last three months.
RCEL Looks 21.8% Undervalued on GF Value™
Avita Medical Inc (NASDAQ: RCEL) has released positive results for its PermeaDerm-I clinical trial, showing its wound matrix is as effective as traditional allografts but 70% cheaper. Despite this, the company remains unprofitable and cash-flow negative, reflected in its high Price-to-Sales ratio. GuruFocus's GF Value™ suggests RCEL is 21.8% undervalued, while insider buying signals confidence in its future.
AVITA Medical Announces Positive PermeaDerm® Study Results Demonstrating 70% Economic Advantage over Allograft and Comparable Clinical Outcomes
AVITA Medical has announced positive results from its PermeaDerm-I clinical study, showing that its biosynthetic wound matrix, PermeaDerm, provides comparable clinical outcomes to cadaveric allograft while offering a 70% economic advantage due to lower product cost and reduced preparation time. The study demonstrated significant cost savings per percent of total body surface area treated and comparable wound healing and safety profiles. This positions PermeaDerm as an efficient and economically favorable alternative for temporary wound coverage.
AVITA Medical’s PermeaDerm shows 70% cost savings over allograft By Investing.com
AVITA Medical announced that its PermeaDerm-I clinical study demonstrated a 70% reduction in treatment costs compared to cadaveric allograft while maintaining similar clinical outcomes. The study involved 40 patients across 11 U.S. burn centers, showing significant cost savings per percent total body surface area treated. PermeaDerm also reduced preparation time by 95.7% and showed comparable wound healing rates, with no adverse events attributed to the product.
AVITA Medical Announces Positive PermeaDerm® Study Results Demonstrating 70% Economic Advantage over Allograft and Comparable Clinical Outcomes
AVITA Medical announced positive results from its PermeaDerm-I study, showing its biosynthetic wound matrix, PermeaDerm, offers a 70% economic advantage over cadaveric allograft due to significantly lower product cost and 95.7% reduced preparation time. The study demonstrated comparable clinical outcomes to allograft, with high rates of graft take and wound healing, and no PermeaDerm-attributed adverse events. These findings establish PermeaDerm as an efficient and cost-effective alternative for temporary wound coverage.
AVITA Medical Announces Positive PermeaDerm® Study Results Demonstrating 70% Economic Advantage over Allograft and Comparable Clinical Outcomes
AVITA Medical announced positive results from its PermeaDerm-I clinical study, showing that PermeaDerm, a biosynthetic wound matrix, provided comparable clinical outcomes to cadaveric allograft while offering a 70% economic advantage due to lower product cost and reduced preparation time. The study demonstrated significant cost savings per percent of total body surface area treated and maintained high rates of graft take and wound healing. PermeaDerm offers an off-the-shelf solution that simplifies workflow and addresses a critical need in acute wound care.
Avita Medical Raises 2026 Revenue Outlook as Q2 Sales Climb 18%
Avita Medical reported strong second-quarter 2026 revenue of $21.7 million, an 18% increase year-over-year, leading the company to raise its full-year revenue guidance to $86 million to $89 million. The company expects continued sequential revenue growth and reiterated its goal to achieve cash-flow breakeven in Q4 2026, driven by product portfolio expansion, improved reimbursement clarity, and international market progress.
Avita Medical Targets Q4 2025 Cash Flow Breakeven as Revenue Growth Builds
Avita Medical (RCEL) expects to achieve cash flow breakeven in Q4 2025, driven by continued sequential revenue growth and controlled operating expenses. CEO Cary Vance highlighted the company's focus on hospital-based acute wound care with a three-product portfolio, targeting a $1.3 billion U.S. addressable market. The company also addressed past reimbursement challenges and plans for future growth beyond breakeven.
Avita Medical Raises 2026 Revenue Outlook as Q2 Sales Climb 18%
Avita Medical (NASDAQ: RCEL) has increased its 2026 revenue guidance to $86 million–$89 million, up from $80 million–$85 million, after a strong second quarter where sales grew 18% year-over-year to $21.7 million. The wound-care company is also on track to achieve cash-flow breakeven in the fourth quarter of 2026, driven by improved financial performance, a narrowed net loss, and reduced cash usage. Growth is expected from increased adoption of its products, potential reimbursement changes from CMS, and international expansion.
Avita Medical Raises 2026 Revenue Outlook as Q2 Sales Climb 18%
Avita Medical (NASDAQ: RCEL) has raised its 2026 revenue guidance to $86 million–$89 million after its second-quarter revenue grew 18% year over year to $21.7 million. The company aims for cash-flow breakeven in Q4 2026 and reported a narrower net loss of $7.7 million and reduced cash use. Growth is expected from its product portfolio, potential CMS reimbursement changes, and international expansion.
Avita Medical Targets Q4 2025 Cash Flow Breakeven as Revenue Growth Builds
Avita Medical (NASDAQ: RCEL) aims to achieve cash flow breakeven in Q4 2025, driven by strong revenue growth and disciplined operating expenses. The company has raised its 2025 revenue guidance to $86 million–$89 million and expects continued expansion for its wound care product portfolio, which currently has about 15% penetration in its core U.S. market. Easing reimbursement uncertainty is also supporting their growth trajectory.
Form 8K Avita Medical Ltd For: 11 August By Investing.com
This article announces the filing of a Form 8K by Avita Medical Ltd, dated August 11. It's a brief report from Investing.com, typical of regulatory filing announcements. The article provides financial data for various indices, commodities, bonds, and shares, as well as a list of popular news and trending stocks.
Avita Medical amends agreement with Stedical Scientific to expand distribution rights
Avita Medical has amended its distribution and manufacturing agreements with Stedical Scientific, securing a right of first offer and refusal to expand its exclusive distribution territory for PermeaDerm products to include the EU, UK, and Australia. The amendment also increases Avita Medical's revenue share from PermeaDerm sales and waives previous minimum revenue sharing payments. This strategic move follows Avita Medical's strong second-quarter earnings report, which exceeded revenue expectations and led to an analyst upgrade.
AVITA Medical Inc (ASX:AVH) Shares Reach 52-Week High at AUD 2.30
AVITA Medical Inc (ASX:AVH) shares reached a new 52-week high of AUD 2.30 on August 12, 2026, closing at AUD 2.28 after a 7.04% increase. The company's market capitalization was approximately AUD 381.9 million, with the stock trading near the top of its annual range of AUD 1.00 to AUD 2.30. This performance highlights significant market activity for AVITA Medical, placing it among healthcare stocks reaching new highs.
Avita Medical amends agreement with Stedical Scientific to expand distribution rights
Avita Medical (NASDAQ:RCEL) has amended its distribution and manufacturing agreements with Stedical Scientific, securing rights to expand PermeaDerm product distribution into Europe, the UK, and Australia. The agreement increases Avita Medical's revenue share from PermeaDerm sales and waives previous minimum payment requirements. This follows Avita Medical's strong Q2 earnings, which led BTIG to upgrade its stock rating to Buy.
Avita Medical Target Price Raised 52% to A$1.90/Share by Canaccord Genuity>AVH.AU
Canaccord Genuity has increased its target price for Avita Medical (AVH.AU) by 52%, setting a new target of A$1.90 per share. This upgrade suggests a strong positive outlook from the analyst firm regarding Avita Medical's future performance.
Investors Can Question AVITA Medical Executives on Aug. 12
AVITA Medical (NASDAQ: RCEL) will host an investor webinar briefing on August 12, 2026, at 4:00 p.m. Pacific Time (August 13, 2026, 9:00 a.m. AEST). President and CEO Cary Vance and CFO David O’Toole will present financial and business highlights from the recent Q2 2026 earnings webcast. Investors can register via Zoom to participate in a Q&A session, and a replay will be available on the company's investor relations website.
AVITA Medical to Host Investor Webinar Briefing | Associated Press | syndication news
AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH) will host an investor webinar briefing and presentation on August 12, 2026, at 4:00 p.m. Pacific Time. The webinar will feature President and CEO Cary Vance and CFO David O’Toole, covering second-quarter 2026 earnings and including a Q&A session. A replay will be available on the AVITA Medical website.
AVITA Medical, Inc. (NASDAQ:RCEL) Is Expected To Breakeven In The Near Future
This article analyzes AVITA Medical, Inc.'s path to profitability, focusing on analyst forecasts for its breakeven point and revenue growth. It highlights the company's expected strong revenue growth and significant earnings improvement in the coming years. The analysis also briefly touches on the importance of management's track record and financial health for future success.
Avita Medical Upgraded to Speculative Buy From Speculative Hold by Bell Potter
Bell Potter has upgraded Avita Medical (ASX:AVH) from a "Speculative Hold" to a "Speculative Buy" rating. This upgrade indicates a more positive outlook on the company's stock by the analyst firm.
AVITA Medical to Host Investor Webinar Briefing
AVITA Medical (NASDAQ: RCEL, ASX: AVH) will host an investor webinar briefing on August 12, 2026, featuring CEO Cary Vance and CFO David O'Toole. The briefing will cover financial and business results from the company's second-quarter 2026 earnings and will include a Q&A session. Shareholders and prospective investors are invited to register via Zoom, with a replay available on the AVITA Medical website.
Avita Medical (NASDAQ:RCEL) Releases Quarterly Earnings Results, Beats Estimates By $0.04 EPS
Avita Medical (NASDAQ:RCEL) announced its quarterly earnings, beating analyst estimates with an adjusted loss of $0.25 per share on revenue of $21.7 million. The company's revenue increased 18% year-over-year, driven by strong RECELL sales, and management raised its 2026 revenue guidance. Avita Medical expects to achieve cash-flow breakeven in the fourth quarter of 2026.
Avita Medical Q2 Earnings Call Highlights
Avita Medical reported strong Q2 2026 results with revenue of $21.7 million, an 18% year-over-year increase, driven by growth in its RECELL product and newer offerings like Cohealyx and PermeaDerm. The company raised its full-year revenue outlook to $86 million to $89 million and anticipates achieving cash-flow breakeven in Q4 2026. Improvements in physician reimbursement for RECELL and the upcoming transition to a new CPT code family are expected to further streamline growth and financial stability.
AVITA Medical Announces Participation at Canaccord Genuity Growth Conference
AVITA Medical, a therapeutic acute wound care company, announced its participation in the Canaccord Genuity 46th Annual Growth Conference. President and CEO Cary Vance will speak on August 12, 2026, and a webcast will be available for investors. The company specializes in solutions like RECELL, Cohealyx, and PermeaDerm for wound healing.
Avita Medical Q2 Earnings Call Highlights
Avita Medical (RCEL) reported strong second-quarter 2026 results, with revenue up 18% year-over-year to $21.7 million, driven by its RECELL product and newer offerings like Cohealyx and PermeaDerm. The company raised its full-year revenue outlook to $86 million to $89 million and anticipates reaching cash-flow breakeven in Q4 2026. Improvements in physician reimbursement for RECELL and the upcoming transition to a new CPT code family are expected to further streamline operations and growth.
AVITA Medical Inc (AVHHL) (Q2 2026) Earnings Call Highlights: Revenue Surges 18% to $21. ...
AVITA Medical Inc (AVHHL) reported strong Q2 2026 results with revenue surging 18% year-over-year to $21.7 million, exceeding $20 million for the first time. The company raised its full-year 2026 revenue guidance and anticipates achieving cash flow breakeven by Q4 2026. While operating and net losses improved, cash reserves remain relatively low, and the company faces challenges with new product adoption and potential transitional impacts from CPT code changes.
Press Release: AVITA Medical Reports Second Quarter Results, Raises 2026 Revenue Guidance, and Expects Fourth Quarter Cash Flow Breakeven
AVITA Medical announced its second-quarter results, showcasing significant growth with record revenue and a raised full-year 2026 revenue guidance. The company reported strong performance from its RECELL GO device and anticipates achieving cash flow breakeven in the fourth quarter of 2026. This positive outlook is supported by increased sales, expanding market penetration, and strategic product development.
AVITA Medical Announces Participation at Canaccord Genuity Growth Conference
AVITA Medical, Inc. announced its participation in the Canaccord Genuity 46th Annual Growth Conference in Boston from August 11–13, 2026. The company's President and CEO, Cary Vance, is scheduled to speak on August 12, 2026, at 8:00 a.m. Eastern Time. A live webcast and replay of his presentation will be available on Avita Medical's investor relations website, and investors attending the conference can request one-on-one meetings with the company.
CEO Cary Vance to Speak at AVITA Medical Conference Aug. 12
AVITA Medical (NASDAQ: RCEL, ASX: AVH) announced its participation in the Canaccord Genuity 46th Annual Growth Conference in Boston from August 11–13, 2026. President and CEO Cary Vance is scheduled to speak on August 12, 2026, at 8:00 a.m. Eastern Time. A live webcast and replay will be available on AVITA Medical’s investor relations website, and investors attending can request one-on-one meetings with the company.
Avita Medical upgrades FY26 revenue guidance
Avita Medical announced a reduced statutory net loss of USD7.7 million for the June quarter and updated its full-year 2026 net revenue guidance to between USD86 million and USD89 million, an increase from its previous forecast. The company also anticipates achieving cashflow breakeven in the fourth quarter. No dividend was declared.
Earnings call transcript: AVITA Medical tops Q2 2026 estimates, shares jump
AVITA Medical reported better-than-expected Q2 2026 results, with narrower losses and higher revenue, leading to an 11.42% after-hours stock jump. The company raised its full-year 2026 revenue guidance to $86 million-$89 million and expects to achieve cash flow breakeven by Q4 2026. Management highlighted strong growth in its wound care portfolio, improved operating efficiency, and positive momentum from product adoption and reimbursement clarity.
AVITA Medical Reports Second Quarter Results, Raises 2026 Revenue Guidance, and Expects Fourth Quarter Cash Flow Breakeven
AVITA Medical reported strong second-quarter 2026 financial results, with net revenue growing 18% year-over-year to a record $21.7 million, driven by the success of RECELL, Cohealyx, and PermeaDerm. The company raised its full-year 2026 net revenue guidance to $86 million to $89 million and anticipates achieving cash flow breakeven in the fourth quarter of 2026. This positive outlook is supported by continued commercial execution and disciplined operating expenses.
